Literature DB >> 2422399

Purification of the Epstein-Barr virus/C3d complement receptor of human B lymphocytes: antigenic and functional properties of the purified protein.

G R Nemerow, M F Siaw, N R Cooper.   

Abstract

The Epstein-Barr virus/C3d receptor (CR2) of human B lymphocytes was purified to homogeneity from Raji cells by immunoaffinity chromatography. The average yield of the 145-kilodalton receptor was 400 pmol (50 micrograms) per 10(10) cells, representing an approximate 75% recovery. The isolated 145-kilodalton protein was antigenically and functionally intact as it reacted with several anti-CR2 monoclonal antibodies and bound purified Epstein-Barr virus and C3d,g. These findings with the purified molecule provide an unequivocal demonstration of the dual receptor functions of this protein.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2422399      PMCID： PMC252969     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  18 in total

1.  Comparison of enzyme-linked immunosorbent assay (ELISA) technique and complement-fixation test for estimation of cytomegalovirus IgG antibody.

Authors:  J C Booth; G Hannington; T A Aziz; H Stern
Journal:  J Clin Pathol       Date:  1979-02       Impact factor: 3.411

2.  Surface markers on human B and T-lymphocytes. IX. Two-color immunofluorescence studies on the association between ebv receptors and complement receptors on the surface of lymphoid cell lines.

Authors:  E Yefenof; G Klein; M Jondal; M B Oldstone
Journal:  Int J Cancer       Date:  1976-06-15       Impact factor: 7.396

3.  Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes.

Authors:  G R Nemerow; M E McNaughton; N R Cooper
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

4.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

5.  Translocation of a hydrocarbon fluorescent probe between Epstein-Barr virus and lymphoid cells: an assay for early events in viral infection.

Authors:  K S Rosenthal; S Yanovich; M Inbar; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity.

Authors:  J H Morrissey
Journal:  Anal Biochem       Date:  1981-11-01       Impact factor: 3.365

8.  Surface markers on human B and T lymphocytes. VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells.

Authors:  M Jondal; G Klein; M B Oldstone; V Bokish; E Yefenof
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

9.  Membrane receptor stripping confirms the association between EBV receptors and complement receptors on the surface of human B lymphoma lines.

Authors:  E Yefenof; G Klein
Journal:  Int J Cancer       Date:  1977-09-15       Impact factor: 7.396

10.  Isolation of Epstein Barr-virus and studies of its neutralization by human IgG and complement.

Authors:  G R Nemerow; N R Cooper
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422
View more
  14 in total

1.  Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells.

Authors:  A Calender; M Billaud; J P Aubry; J Banchereau; M Vuillaume; G M Lenoir
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

Review 2.  Epstein-Barr virus tissue tropism: a major determinant of immunopathogenesis.

Authors:  L Hutt-Fletcher
Journal:  Springer Semin Immunopathol       Date:  1991

3.  The detection of Epstein-Barr virus in hairy cell leukemia cells by in situ hybridization.

Authors:  B C Wolf; A W Martin; R S Neiman; A J Janckila; L T Yam; A Caracansi; B A Leav; R Winpenny; D S Schultz; H J Wolfe
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

4.  An EBV-transformed owl monkey B-lymphocyte cell line.

Authors:  J G Scammell; P D Reynolds; M Y Elkhalifa; J A Tucker; C M Moore
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-02       Impact factor: 2.416

5.  Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.

Authors:  G R Nemerow; C Mold; V K Schwend; V Tollefson; N R Cooper
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

6.  Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes.

Authors:  M D Moore; N R Cooper; B F Tack; G R Nemerow
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

7.  Non-healing pharyngeal ulcer in a middle-aged Caucasian man.

Authors:  Nwabundo Nwankwo; Raya Saba; Aibek E Mirrakhimov; Shesh Rao
Journal:  BMJ Case Rep       Date:  2013-03-07

8.  Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes.

Authors:  J Tanner; Y Whang; J Sample; A Sears; E Kieff
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

9.  Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection.

Authors:  G R Nemerow; J J Mullen; P W Dickson; N R Cooper
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

10.  T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE).

Authors:  E Levy; J Ambrus; L Kahl; H Molina; K Tung; V M Holers
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.